Rosuvastatin
Also known as: Crestor
HMG-CoA Reductase Inhibitor | Statin for Lipid Management
Overview
Rosuvastatin is the most potent statin currently available, offering the greatest LDL cholesterol reduction per milligram among all HMG-CoA reductase inhibitors. FDA-approved in 2003 under the brand name Crestor, it rapidly became one of the most prescribed medications worldwide for hyperlipidemia and cardiovascular risk reduction. Rosuvastatin is particularly popular in the anabolic steroid community, where it is widely used to manage lipid disturbances caused by androgenic-anabolic steroids (AAS), especially oral compounds like oxandrolone, stanozolol, and methandrostenolone that are notorious for dramatically worsening lipid profiles. Its long 19-hour half-life allows convenient once-daily dosing, and its hydrophilic nature gives it hepatic selectivity with a potentially lower incidence of muscle-related side effects compared to lipophilic statins like atorvastatin and simvastatin. The JUPITER trial demonstrated that rosuvastatin significantly reduces cardiovascular events even in individuals with normal LDL but elevated high-sensitivity C-reactive protein (hsCRP), highlighting its anti-inflammatory properties beyond pure lipid lowering.
Key benefits
- Most potent statin available, with LDL reductions of 45-63% depending on dose
- Long half-life (19 hours) allows flexible once-daily dosing at any time of day
- Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
- Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
- Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
- Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
- Proven cardiovascular event and mortality reduction in large-scale clinical trials
- Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Mechanism of action
Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface. The increased density of LDL receptors enhances clearance of LDL cholesterol and its precursors (VLDL and IDL) from the bloodstream. Rosuvastatin has the highest binding affinity for HMG-CoA reductase among all available statins, which accounts for its superior potency. Beyond lipid lowering, rosuvastatin exerts pleiotropic effects that contribute to cardiovascular protection: improvement of endothelial function via increased nitric oxide bioavailability, reduction of vascular inflammation (lowering hsCRP by 30-50%), stabilization of atherosclerotic plaques, decreased oxidative stress, and modest antithrombotic effects. In the context of AAS use, rosuvastatin counteracts the characteristic lipid derangement pattern caused by androgens -- namely suppressed HDL cholesterol and elevated LDL cholesterol -- by directly reducing LDL production and, to a lesser extent, raising HDL through unclear mechanisms thought to involve apolipoprotein A-I upregulation.
Molecular data
- Type
- Synthetic statin (C22H28FN3O6S-Ca)
- Half-life
- ~19 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Lipid Management
Prevention
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 5-10 mg/day | Once daily | — |
| — | 10-20 mg/day | Once daily | — |
| — | 5-20 mg/day | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
- Headache
- Nausea and abdominal discomfort
- Weakness or fatigue
- Constipation or diarrhea
Rare side effects
- Liver enzyme elevation (ALT/AST) -- typically mild and transient, clinically significant elevation (>3x ULN) occurs in <1% of users
- Rhabdomyolysis -- extremely rare but potentially life-threatening breakdown of muscle tissue, risk increases with higher doses, drug interactions, and renal impairment
- New-onset type 2 diabetes -- modest increase in risk (approximately 1 additional case per 250 patients treated for 4 years), primarily in those with pre-existing risk factors
- Memory impairment or cognitive effects -- rare, reversible upon discontinuation, FDA-required class labeling but causal link debated
- Proteinuria -- primarily seen at the 40 mg dose, generally tubular in origin and not indicative of renal damage
Contraindications
- Active liver disease or unexplained persistent elevations in hepatic transaminases
- Known hypersensitivity to rosuvastatin or any excipients
- Pregnancy and breastfeeding (Category X -- statins are teratogenic)
- Concomitant use with cyclosporine (at all doses of rosuvastatin)
- Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
Monitoring
- Lipid panel: at baseline, 4-8 weeks after initiation or dose change, then every 6-12 months
- Liver enzymes (ALT/AST): at baseline and as clinically indicated (routine periodic monitoring no longer universally recommended but prudent for AAS users)
- Creatine kinase (CK): at baseline if at elevated risk for myopathy; repeat if muscle symptoms develop
- Fasting glucose / HbA1c: periodically, given the modest diabetes risk associated with statin therapy
- Renal function: at baseline and periodically, especially at higher doses or with concurrent nephrotoxic agents
References
Primary literature and clinical-trial data informing this entry.